Perimenopause Treatments Are Multiplying — But Are We Still Treating a Life Stage, or a Disease?
A new Medscape article surveys the expanding landscape of perimenopause treatments — from established hormone therapy to neurokinin receptor antagonists to experimental supplements like NRPT and cendifensine. It is a genuinely useful clinical inventory. But read alongside our earlier essay on menopause as a physiological stage rather than a disease, it raises the same underlying question in sharper form: as the list of treatable "symptom clusters" keeps growing, are clinicians still treating maladaptation to a natural transition, or are they gradually re-describing the transition itself as a condition requiring correction?
What the Article Gets Right
The piece performs a real service in acknowledging diagnostic uncertainty rather than false precision. Kelly Saunders, MD, notes that hormone testing is less useful than symptom history for confirming the perimenopausal transition, and that unpredictable bleeding often reflects hormone instability rather than disease — a distinction that matters enormously for avoiding unnecessary workups for fibroids or precancer. Karen Adams, MD, makes the same point from a different angle: "It's not so much that we want the periods regular. It's that we want hormone stabilization." This is biology-first thinking in practice — treating erratic hormonal signaling as a normal, if disruptive, feature of ovarian aging, not automatically a pathology to be chased down with invasive testing.
The article's treatment of nonhormonal options is similarly careful. NK3R antagonists like fezolinetant and elinzanetant are presented as legitimate, mechanism-specific tools for vasomotor symptoms, with real caveats — liver enzyme monitoring, and honest acknowledgment that testosterone therapies for perimenopausal women remain unapproved and used off-label due to unresolved cardiovascular risk. This is exactly the kind of qualified, tool-not-cure framing that a physiological view of menopause calls for.
Where the Growing Treatment List Risks Drifting
The concern is less about any single treatment and more about the cumulative effect of the list itself. The article catalogues estrogen therapy, progestin IUDs, testosterone, SSRIs, E4/drospirenone, two separate NK3R antagonists, NRPT supplementation, cendifensine, ashwagandha, melatonin, magnesium, maca root, and exercise protocols — an impressive range of interventions, each targeting a slightly different symptom domain: cycle irregularity, vasomotor symptoms, libido, mood, sleep, brain fog. Individually, each is a reasonable, evidence-seeking answer to a specific complaint. Collectively, the list starts to read as if perimenopause itself is the diagnosis requiring a matching pharmacy, rather than a physiological transition during which some women develop specific, treatable maladaptations that happen to cluster in time.
This is precisely the drift our earlier essay identified in the "hidden burdens" article on postmenopause: a useful symptom inventory can quietly become the primary explanatory framework, displacing the more basic question of whether a given complaint is truly menopause-linked maladaptation or an independent process — vascular, metabolic, or psychiatric — that happens to appear around the same age. The new article doesn't ignore this risk; Ruta Nonacs, MD, explicitly notes hormone therapy is not first-line for depression and anxiety even though hormonal changes can contribute to both. But the sheer proliferation of named, marketed interventions for perimenopause, many still investigational, makes it easy for both patients and clinicians to start treating the transition itself as the target rather than treating specific, diagnosed maladaptation within it.
The E4 and Testosterone Examples Show the Right Instinct
Two details in the article actually model the biology-first approach well, and are worth highlighting rather than criticizing. Estetrol (E4) is described honestly, including its drawback profile — breakthrough bleeding in a third of new users, no generic version, inconsistent insurance coverage — rather than presented as a uniformly superior option. And testosterone therapy is flagged clearly as anecdotal and off-label, with real cardiovascular uncertainty, rather than smoothed over because patients want it. This is the correct posture: treatments as tools matched to demonstrated maladaptation and patient-specific risk, not blanket corrections applied to a life stage.
Emerging Compounds Deserve the Same Scrutiny, Not More Enthusiasm
Cendifensine's phase 2 results — a 92% reduction in hot flash frequency — are striking, and NRPT's pilot data on symptom reduction are worth watching. But a biology-first framework asks a specific question before enthusiasm: are these compounds treating a maladaptive process (KNDy neuron hyperstimulation driving hot flashes, in cendifensine's case) or simply suppressing a normal physiological signal because it's uncomfortable? The mechanistic specificity described for cendifensine — acting on the exact neural pathway that produces hot flashes when estrogen drops — is reassuring precisely because it targets a defined maladaptive symptom rather than treating "perimenopause" as an undifferentiated target. That's the standard every new compound on this growing list should be held to before we add it to the shelf.
Adams' Diagnostic Point Deserves the Last Word
The article's most quietly important observation may be this: "On average, women go to five different clinicians before their perimenopausal symptoms get diagnosed and treated." That statistic reflects a real diagnostic failure — women's genuine, treatable maladaptation is too often missed rather than overtreated. Getting this right requires holding two things at once, which is the whole point of the biology-first framework: menopause and perimenopause are physiological, not diseases in themselves, and clinicians should not chase every symptom back to hormones by default — but when maladaptation is real, as it clearly is for a majority of women with vasomotor or genitourinary symptoms, it deserves to be found faster and treated seriously, with tools matched to mechanism rather than applied indiscriminately to the transition as a whole.
The expanding menu of perimenopause treatments is, on balance, good news — more mechanistic precision, more honest safety data, more options matched to specific complaints. The task now is making sure that abundance of options doesn't quietly relabel a normal biological transition as the disease itself.
Comments
Post a Comment